1. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab

   • Tiago Torres

   Current Opinion 02 August 2017 Pages: 1493 - 1503

   

2. Drugs in Clinical Development for Fungal Infections

   • Maria F. Gonzalez-Lara
   • Jose Sifuentes-Osornio
   • Luis Ostrosky-Zeichner

   Leading Article 24 August 2017 Pages: 1505 - 1518

   

3. Pharmacotherapy of Anal Cancer

   • Jane E. Rogers
   • Cathy Eng

   Therapy in Practice 02 August 2017 Pages: 1519 - 1530

4. Current and Emerging Options for the Management of Inherited von Willebrand Disease

   • Jessica M. Heijdra
   • Marjon H. Cnossen
   • Frank W. G. Leebeek

   Review Article Open access 08 August 2017 Pages: 1531 - 1547

   

5. Pharmacotherapy of Myelofibrosis

   • Douglas Tremblay
   • Bridget Marcellino
   • John Mascarenhas

   Review Article 08 August 2017 Pages: 1549 - 1563

6. Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer

   • Lesley J. Scott

   Adis Drug Evaluation 17 August 2017 Pages: 1565 - 1576

7. Canagliflozin: A Review in Type 2 Diabetes

   • Emma D. Deeks
   • André J. Scheen

   Adis Drug Evaluation 23 August 2017 Pages: 1577 - 1592

   

8. Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability

   • Esther S. Kim

   Adis Drug Evaluation 01 September 2017 Pages: 1593 - 1602

9. Inotuzumab Ozogamicin: First Global Approval

   • Yvette N. Lamb

   AdisInsight Report 17 August 2017 Pages: 1603 - 1610

   

10. Erratum to: A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?

    • Wendy L. St. Peter
    • Lori D. Wazny
    • Joanna Q. Hudson

    Erratum 07 August 2017 Pages: 1611 - 1611